ClinicalTrials.gg
RecruitingNCT07316296AnTi-FREEZEUpdated Feb 27, 2026

Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach

A Phase 3 interventional study of Atomoxetine and Placebo in Parkinson's Disease (PD), Freezing of Gait and Freezing of Gait Symptoms in Parkinson Disease, sponsored by Radboud University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Radboud University Medical Center · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Parkinson Disease by Radboud University Medical Center — 6 open to participants now, 12 under way, 1 of them phase 3. Parkinson Disease · Radboud University Medical Center.

Planned enrollment
16th of 22
60 · median 188
Started
2026
the only one that year
Phase 3
5 of 34
1 open now
Primary completion
2027-07
later than 9 of 11 live
Registered
34th of 34
by date

Among the 34 studies in Parkinson Disease by Radboud University Medical Center, this one is the 16th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 3, reaches primary completion later than 9 of the 11 other live ones, and was the 34th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 34 studies in Parkinson Disease by Radboud University Medical Center are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Parkinson Disease by Radboud University Medical Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the medication atomoxetine can reduce freezing of gait in people with Parkinson's disease. The main questions it aims to answer is:

Does atomoxetine reduce the frequency or severity of freezing of gait? What role does noradrenaline play in freezing of gait?

Researchers will compare atomoxetine to a placebo to see if atomoxetine can improve freezing of gait in people with Parkinson's disease.

Participants will:

Visit the study site for measurements Take atomoxetine or placebo Perform walking assessments and undergo MRI Complete questionnaires about anxiety, stress, and quality of life

03

Conditions studied

  • Parkinson's Disease (PD)
  • Freezing of Gait
  • Freezing of Gait Symptoms in Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older;
  • Diagnosis of idiopathic PD according to MDS Diagnostic Criteria;
  • Stabilised on optimal dopaminergic PD treatment for a minimum of four weeks prior to the baseline visit (Visit 1) and for the duration of the trial;
  • Presence of FOG symptoms on a daily basis;
  • Ability to walk for 10-meters unaided in the dopaminergic ON-state;
  • Ability to provide written in accordance with ICH-GCP and local regulations;
  • Willing and able to undergo all clinical trial assessments.

Exclusion criteria

Exclusion Criteria:

  • Current and/or previous (within 3 months) participation in a clinical trial;
  • Any for undergoing MRI-scanning (e.g. claustrophobia or metal parts within the body such as DBS, an infusion pump or a pacemaker);
  • Co-morbidity that significantly impacts ambulation (e.g. orthopaedic or rheumatological ailments);
  • Severe cognitive impairment hampering the ability to comply with the study protocol;
  • Active psychosis that would impact the ability to comply with the study protocol;
  • Severe cardiovascular disorders: severe hypertension (Sustained (Sitting) hypertension of ≥180 mmHg systolic or ≥110 mmHg diastolic, defined by the average of three observations, each at least 3 minutes apart, with the participant having assumed the required position for at least 3 minutes), heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias, long syndrome (QTc > 500ms Bazett-formula) and channelopathies that in the opinion of the study PI would significantly compromise participant safety;
  • Severe cerebrovascular disorders: cerebral aneurysm or recent/significant stroke;
  • Hepatic or renal insufficiency that in the opinion of the Principal Investigator would impact on the ability of the participant to safely participate;
  • Narrow angle glaucoma;
  • (History of) pheochromocytoma;
  • Use of noradrenergic agents;
  • Use of CYP2D6 inhibitors (SSRIs, quinidine, terbinafine);
  • Use of high dose salbutamol (or other beta2 agonists) that in the opinion of the Principal Investigator would impact on the ability of the participant to safely participate;
  • Pregnancy and/or breastfeeding;
  • Known to atomoxetine.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Atomoxetine in visit 2 and placebo in visit 3

    Drug: Atomoxetine · Drug: Placebo

  • Experimental
    Placebo in visit 2 and atomoxetine in visit 3

    Drug: Atomoxetine · Drug: Placebo

Interventions

  • Single dose, 40mg atomoxetine, capsule

  • DrugPlacebo

    Single dose, placebo (microcrystalline cellulose), capsule

06

What researchers measure

Primary outcomes

  1. The percentage of time frozen in the dopaminergic OFF-state

    Time frame: Baseline, visit 2 (one week after baseline) and visit 3 (one week after visit 2).

Secondary outcomes

  1. The percentage of time frozen in the dopaminergic ON-state

    Time frame: Baseline, visit 2 (one week after baseline) and visit 3 (one week after visit 2).

  2. The brain network integration-segregation coefficient

    Time frame: Visit 2 (one week after baseline) and visit 3 (one week after visit 2).

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.

Of 68 phase 3 interventional studies under Parkinson Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Jan 5, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07316296
Collaborators
University of Waterloo, Macquarie University, Australia
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Jan 1, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atomoxetine

Start the discussion